Welcome to Calon Cardio-Technology
Chronic heart failure is a serious, often terminal, medical condition that occurs when the heart is unable to pump sufficient blood to meet the demands of the body. It currently affects around 26 million people in the developed world and the number of sufferers is rapidly growing.
Traditionally, conservative medical management and cardiac resynchronization therapy have been used to prolong survival and improve quality of life. However, these therapies are only partially successful, and many patients progress to advanced heart failure which carries a terminal prognosis and a very poor quality of life. Until recently only heart transplants offered a cure for advanced heart failure, but the very limited supply of donor hearts, currently approximately 4000 a year worldwide, means that transplants are reserved only for a very lucky few.
In the last years, fully implanted heart assist pumps, commonly known as ventricular assist devices (VADs), have become available as a viable therapy for advanced heart failure. These pumps, which boost the heart’s output and reduce the stress on the heart, have been demonstrated to be clinically effective with significant improvements in survival compared to medical management.
Early generation pumps were large, heavy, required highly invasive surgery and had limited reliability and durability. More recent technology has allowed VADs to become smaller and easier to implant, however, over time the adverse effects of these pumps on blood have become apparent, with evidence of haemolysis and a significant incidence of thrombus formation resulting in adverse medical events.
The technology being developed by Calon Cardio-Technology – Calon – aims to address these problems. Calon is developing a pump, the MiniVADTM to be implanted directly into the failing heart, driven by an embedded electric motor and powered by a compact battery pack worn by the user. Calon’s intent is to develop and commercialise a pump that can boost the output of the failing heart to improve quality of life, and slow or halt the progress of the condition.
Through the application of advanced computational modelling technology and in vitro testing developed in-house, Calon’s design approach has resulted in a miniaturized pump of reduced size and weight, while retaining the required pumping output (blood flow). Most importantly, pre-clinical testing has shown that the MiniVADTM minimises both blood damage and the risk of thrombus formation. The MiniVADTM should also lead to a significantly improve the affordability of treating advanced heart failure and improve patient access to VAD treatment.
Disclaimer: Calon Cardio’s VAD devices are not available for sale, including in the United States of America